NeoOncoRx licenses Johnson Matthey platinum drug
Executive Summary
NeoTherapeutics' oncology subsidiary NeoOncoRx has acquired the worldwide rights to develop and market Johnson Matthey PLC's satraplatin (JM-216), a platinum-derived cytotoxin for treating cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice